Telomerase-specific fluorescent navigation system for lung cancer surgery

用于肺癌手术的端粒酶特异性荧光导航系统

基本信息

  • 批准号:
    17390381
  • 负责人:
  • 金额:
    $ 9.86万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and well studied; the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 contains the replication cassette, in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of El genes, and the GFP gene for monitoring viral replication. The hTERT is the catalytic subunit of telomerase, which is highly active in cancer cells, but is quiescent in most normal somatic cells. When the human lung cancer cell line H1299 was infected with OBP-401, the virus replicated in tumor cells and showed strong green signals. In contrast, infection of OBP-401 did not show any signals in normal cells such as fibroblasts. We also found that established subcutaneous tumors could be visualized following intratumoral injection of OBP-401. H1299 human lung tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 1 x 10^8 plaque forming units (PFU) of OBP-401. Within 24 hours of treatment, the fluorescence of the expressed GFP became visible by 3CCD camera in these tumors. Moreover, intrathoracic administration of OBP-401 could visualize disseminated A549 tumor nodules in mice following intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of OBP-401 might be a useful diagnostic method that provides a foundation for future clinical application.
目前可用的体内肿瘤检测方法,如x射线、计算机断层扫描和超声检查是无创的,并且研究得很好;然而,这些图像并不是针对肿瘤的。活体肿瘤细胞的直接光学成像可以清楚地将其与周围的正常组织区分开来,这在临床上可能是有用的。在这里,我们描述了一种可视化肿瘤的新方法,其荧光可以通过表达绿色荧光蛋白(GFP) (OBP-401)的端粒酶特异性复制能力腺病毒来检测。OBP-401包含复制盒,其中人类端粒酶逆转录酶(hTERT)启动子驱动El基因的表达,以及用于监测病毒复制的GFP基因。hTERT是端粒酶的催化亚基,端粒酶在癌细胞中高度活跃,但在大多数正常体细胞中处于静止状态。当OBP-401感染人肺癌细胞系H1299时,病毒在肿瘤细胞中复制,并表现出强烈的绿色信号。相比之下,OBP-401感染在正常细胞如成纤维细胞中未显示任何信号。我们还发现,瘤内注射OBP-401后,已建立的皮下肿瘤可以可视化。移植到BALB/c nu/nu小鼠体内的H1299人肺肿瘤瘤内注射1 × 10^8斑块形成单位(PFU)的OBP-401。在治疗24小时内,通过3CCD相机在这些肿瘤中可以看到表达的GFP的荧光。此外,胸廓内给药OBP-401可以显示胸廓内植入小鼠弥散性A549肿瘤结节。结果表明,瘤内或胸内注射OBP-401可能是一种有效的诊断方法,为今后的临床应用提供了基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy
  • DOI:
    10.1002/ijc.21846
  • 发表时间:
    2006-07-15
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Fujiwara, Toshiya;Kagawa, Shunsuke;Fujiwara, Toshiyoshi
  • 通讯作者:
    Fujiwara, Toshiyoshi
悪性腫瘍に対するウイルス製剤Telomelysinの臨床開発.
用于恶性肿瘤的病毒药物 Telomelysin 的临床开发。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Watanabe;T.;藤原俊義
  • 通讯作者:
    藤原俊義
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus
  • DOI:
    10.1038/nm1404
  • 发表时间:
    2006-10-01
  • 期刊:
  • 影响因子:
    82.9
  • 作者:
    Kishimoto, Hiroyuki;Kojima, Toru;Fujiwara, Toshiyoshi
  • 通讯作者:
    Fujiwara, Toshiyoshi
Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD)
  • DOI:
    10.1038/sj.onc.1208460
  • 发表时间:
    2005-04-28
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Taki, M;Kagawa, S;Fujiwara, T
  • 通讯作者:
    Fujiwara, T
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
组蛋白脱乙酰酶抑制剂 FR901228 增强端粒酶特异性复制选择性腺病毒药物 OBP-301 在人肺癌细胞中的抗肿瘤作用
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FUJIWARA Toshiyoshi其他文献

FUJIWARA Toshiyoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FUJIWARA Toshiyoshi', 18)}}的其他基金

Development of the Dual fluorescent cytology with tumor-specific viruses for gastrointestinal cancer precision medicine
开发肿瘤特异性病毒双荧光细胞学用于胃肠道癌症精准医疗
  • 批准号:
    16H05416
  • 财政年份:
    2016
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Fluorescent virus-guided capturing of epithelial-mesenchymal transition (EMT)-induced circulating tumor cells (CTCs) for genetic analysis
荧光病毒引导捕获上皮间质转化 (EMT) 诱导的循环肿瘤细胞 (CTC) 用于遗传分析
  • 批准号:
    25670580
  • 财政年份:
    2013
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
"Cell-in-cell" activity-based tumor-specific delivery of biologics
基于“细胞内细胞”活性的肿瘤特异性生物制剂递送
  • 批准号:
    25293283
  • 财政年份:
    2013
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular therapy for gastric cancer using HER2-extracellular domain-expressing adenovirus
使用表达 HER2 胞外结构域的腺病毒进行胃癌分子治疗
  • 批准号:
    22390256
  • 财政年份:
    2010
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Telomerase-specific virotherapy for malignant mesothelioma
端粒酶特异性病毒疗法治疗恶性间皮瘤
  • 批准号:
    19390365
  • 财政年份:
    2007
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular Fluorescent Imaging of Metastatic Tumors with Conditionally Replication-Selective Adenovirus and GFP Gene
使用条件复制选择性腺病毒和 GFP 基因对转移性肿瘤进行分子荧光成像
  • 批准号:
    15591475
  • 财政年份:
    2003
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular Analysis of Resistance to p53 Gene Therapy in Human Lung Cancer
人类肺癌 p53 基因治疗耐药性的分子分析
  • 批准号:
    13671390
  • 财政年份:
    2001
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Gene Therapy for Lung Cancer using a Novel Antiangiogenic Factor BAI1
使用新型抗血管生成因子 BAI1 开发肺癌基因疗法
  • 批准号:
    11671325
  • 财政年份:
    1999
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
推进溶瘤腺病毒治疗胰腺癌的系统递送
  • 批准号:
    10734709
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
Development of antibodies to specific cell surface markers to assess macrophage polarization during Adenovirus 14 and 14p1 infection in the Syrian hamster
开发针对特定细胞表面标记物的抗体,以评估叙利亚仓鼠腺病毒 14 和 14p1 感染期间的巨噬细胞极化
  • 批准号:
    10725702
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
Development of novel immunotherapy with stem cells loaded oncolytic adenovirus for advanced cancers
开发携带溶瘤腺病毒的干细胞治疗晚期癌症的新型免疫疗法
  • 批准号:
    23K19510
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
INVECTA: Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications
INVECTA:针对治疗应用的新型腺病毒载体的综合表征
  • 批准号:
    EP/Y036883/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Research Grant
iAds: Intelligent Design Of Adenovirus Vectors
iAds:腺病毒载体的智能设计
  • 批准号:
    10079200
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
    EU-Funded
Development of recombinant adenovirus medicines
重组腺病毒药物的开发
  • 批准号:
    23H00552
  • 财政年份:
    2023
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla
限制腺病毒载体治疗肿瘤的机制因素
  • 批准号:
    10618174
  • 财政年份:
    2022
  • 资助金额:
    $ 9.86万
  • 项目类别:
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC
先进的溶瘤腺病毒实现 PDAC 的系统治疗
  • 批准号:
    10566530
  • 财政年份:
    2022
  • 资助金额:
    $ 9.86万
  • 项目类别:
Epigenetic Regulation of the Adenovirus Genome
腺病毒基因组的表观遗传调控
  • 批准号:
    468931
  • 财政年份:
    2022
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Operating Grants
Investigating a Novel Example of Adenovirus Viral Mimicry and Its Effect on Transcription
研究腺病毒病毒拟态的新例子及其对转录的影响
  • 批准号:
    570188-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 9.86万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了